{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T00:29:49Z","timestamp":1793320189731,"version":"4.5.0"},"reference-count":91,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,12,31]]},"DOI":"10.7759\/cureus.100490","type":"journal-article","created":{"date-parts":[[2025,12,31]],"date-time":"2025-12-31T14:58:37Z","timestamp":1767193117000},"source":"Crossref","is-referenced-by-count":1,"title":["The Present and Future of Pain Management in Patients With Chronic Kidney Disease: A Narrative Review"],"prefix":"10.7759","author":[{"given":"Igor","family":"Wilderman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Sarzetto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Budvin","family":"Wijetillake","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sydney","family":"Verdun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfae048","article-title":"Global health inequalities of chronic kidney disease: A meta-analysis","volume":"39","author":"Duff R","year":"2024","unstructured":"Duff R, Awofala O, Arshad MT, Lambourg E, Gallacher P, Dhaun N, Bell S. Global health inequalities of chronic kidney disease: A meta-analysis. Nephrol Dial Transplant. 2024, 39:1692-709. 10.1093\/ndt\/gfae048","journal-title":"Nephrol Dial Transplant"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfm153","article-title":"Dialysis or not? A comparative survival study of patients over 75 years with chronic kidney disease stage 5","volume":"22","author":"Murtagh FE","year":"2007","unstructured":"Murtagh FE, Marsh JE, Donohoe P, Ekbal NJ, Sheerin NS, Harris FE. Dialysis or not? A comparative survival study of patients over 75 years with chronic kidney disease stage 5. Nephrol Dial Transplant. 2007, 22:1955-62. 10.1093\/ndt\/gfm153","journal-title":"Nephrol Dial Transplant"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1038\/ki.2015.228","article-title":"Comorbidity as a driver of adverse outcomes in people with chronic kidney disease","volume":"88","author":"Tonelli M","year":"2015","unstructured":"Tonelli M, Wiebe N, Guthrie B, et al.. Comorbidity as a driver of adverse outcomes in people with chronic kidney disease. Kidney Int. 2015, 88:859-66. 10.1038\/ki.2015.228","journal-title":"Kidney Int"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1111\/sdi.12196","article-title":"Pain in chronic kidney disease: A scoping review","volume":"27","author":"Davison SN","year":"2014","unstructured":"Davison SN, Koncicki H, Brennan F. Pain in chronic kidney disease: A scoping review. Semin Dial. 2014, 27:188-204. 10.1111\/sdi.12196","journal-title":"Semin Dial"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.2147\/JPR.S125270","article-title":"Pharmacotherapeutic considerations for chronic pain in chronic kidney and end-stage renal disease","volume":"9","author":"Mathew RO","year":"2016","unstructured":"Mathew RO, Bettinger JJ, Wegrzyn EL, Fudin J. Pharmacotherapeutic considerations for chronic pain in chronic kidney and end-stage renal disease. J Pain Res. 2016, 9:1191-5. 10.2147\/JPR.S125270","journal-title":"J Pain Res"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1097\/MNH.0000000000000646","article-title":"Pain management in patients with chronic kidney disease and end-stage kidney disease","volume":"29","author":"Roy PJ","year":"2020","unstructured":"Roy PJ, Weltman M, Dember LM, Liebschutz J, Jhamb M. Pain management in patients with chronic kidney disease and end-stage kidney disease. Curr Opin Nephrol Hypertens. 2020, 29:671-80. 10.1097\/MNH.0000000000000646","journal-title":"Curr Opin Nephrol Hypertens"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.2215\/CJN.00820207","article-title":"Pain, sleep disturbance, and quality of life in patients with chronic kidney disease","volume":"2","author":"Cohen SD","year":"2007","unstructured":"Cohen SD, Patel SS, Khetpal P, Peterson RA, Kimmel PL. Pain, sleep disturbance, and quality of life in patients with chronic kidney disease. Clin J Am Soc Nephrol. 2007, 2:919-25. 10.2215\/CJN.00820207","journal-title":"Clin J Am Soc Nephrol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1053\/j.ajkd.2023.07.021","article-title":"Apathy symptoms, physical and cognitive function, health-related quality of life, and mortality in older patients with CKD: A longitudinal observational study","volume":"83","author":"Voorend CG","year":"2024","unstructured":"Voorend CG, van Buren M, Berkhout-Byrne NC, et al.. Apathy symptoms, physical and cognitive function, health-related quality of life, and mortality in older patients with CKD: A longitudinal observational study. Am J Kidney Dis. 2024, 83:162-172.e1. 10.1053\/j.ajkd.2023.07.021","journal-title":"Am J Kidney Dis"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.12688\/f1000research.2-28.v3","article-title":"Management of acute and post-operative pain in chronic kidney disease","volume":"2","author":"Parmar MS","year":"2013","unstructured":"Parmar MS, Parmar KS. Management of acute and post-operative pain in chronic kidney disease. F1000Res. 2013, 2:28. 10.12688\/f1000research.2-28.v3","journal-title":"F1000Res"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1053\/j.ajkd.2003.08.025","article-title":"Pain in hemodialysis patients: Prevalence, cause, severity, and management","volume":"42","author":"Davison SN","year":"2003","unstructured":"Davison SN. Pain in hemodialysis patients: Prevalence, cause, severity, and management. Am J Kidney Dis. 2003, 42:1239-47. 10.1053\/j.ajkd.2003.08.025","journal-title":"Am J Kidney Dis"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1097\/01.NPR.0000615544.81303.9c","article-title":"Pain management for patients with chronic kidney disease in the primary care setting","volume":"45","author":"Lowe KM","year":"2020","unstructured":"Lowe KM, Robinson DR Jr. Pain management for patients with chronic kidney disease in the primary care setting. Nurse Pract. 2020, 45:18-26. 10.1097\/01.NPR.0000615544.81303.9c","journal-title":"Nurse Pract"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.2215\/CJN.05180418","article-title":"Clinical pharmacology considerations in pain management in patients with advanced kidney failure","volume":"14","author":"Davison SN","year":"2019","unstructured":"Davison SN. Clinical pharmacology considerations in pain management in patients with advanced kidney failure. Clin J Am Soc Nephrol. 2019, 14:917-31. 10.2215\/CJN.05180418","journal-title":"Clin J Am Soc Nephrol"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.2215\/CJN.06520714","article-title":"Chronic pain and analgesic use in CKD: Implications for patient safety","volume":"10","author":"Wu J","year":"2015","unstructured":"Wu J, Ginsberg JS, Zhan M, Diamantidis CJ, Chen J, Woods C, Fink JC. Chronic pain and analgesic use in CKD: Implications for patient safety. Clin J Am Soc Nephrol. 2015, 10:435-42. 10.2215\/CJN.06520714","journal-title":"Clin J Am Soc Nephrol"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpain.2004.11.009","article-title":"Treatment of pain in patients with renal insufficiency: The World Health Organization three-step ladder adapted","volume":"6","author":"Launay-Vacher V","year":"2005","unstructured":"Launay-Vacher V, Karie S, Fau JB, Izzedine H, Deray G. Treatment of pain in patients with renal insufficiency: The World Health Organization three-step ladder adapted. J Pain. 2005, 6:137-48. 10.1016\/j.jpain.2004.11.009","journal-title":"J Pain"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1093\/ckj\/sfx080","article-title":"2017 update on pain management in patients with chronic kidney disease","volume":"10","author":"Pham PC","year":"2017","unstructured":"Pham PC, Khaing K, Sievers TM, et al.. 2017 update on pain management in patients with chronic kidney disease. Clin Kidney J. 2017, 10:688-97. 10.1093\/ckj\/sfx080","journal-title":"Clin Kidney J"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1016\/j.bja.2021.08.035","article-title":"Analgesic use and associated adverse events in patients with chronic kidney disease: A systematic review and meta-analysis","volume":"128","author":"Lambourg E","year":"2022","unstructured":"Lambourg E, Colvin L, Guthrie G, Walker H, Bell S. Analgesic use and associated adverse events in patients with chronic kidney disease: A systematic review and meta-analysis. Br J Anaesth. 2022, 128:546-61. 10.1016\/j.bja.2021.08.035","journal-title":"Br J Anaesth"},{"key":"ref17","unstructured":"2024 Canadian opioid prescribing guideline. (2024). Accessed. November 4, 2025: https:\/\/www.substanceusehealth.ca\/resource\/2024-canadian-opioid-prescribing-guideline."},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.15585\/mmwr.rr7103a1","article-title":"CDC clinical practice guideline for prescribing opioids for pain - United States, 2022","volume":"71","author":"Dowell D","year":"2022","unstructured":"Dowell D, Ragan KR, Jones CM, Baldwin GT, Chou R. CDC clinical practice guideline for prescribing opioids for pain - United States, 2022. MMWR Recomm Rep. 2022, 71:1-95. 10.15585\/mmwr.rr7103a1","journal-title":"MMWR Recomm Rep"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1053\/j.ajkd.2020.03.023","article-title":"NSAIDs in CKD: Are they safe?","volume":"76","author":"Baker M","year":"2020","unstructured":"Baker M, Perazella MA. NSAIDs in CKD: Are they safe?. Am J Kidney Dis. 2020, 76:546-57. 10.1053\/j.ajkd.2020.03.023","journal-title":"Am J Kidney Dis"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjmed.2006.02.015","article-title":"NSAID use and progression of chronic kidney disease","volume":"120","author":"Gooch K","year":"2007","unstructured":"Gooch K, Culleton BF, Manns BJ, et al.. NSAID use and progression of chronic kidney disease. Am J Med. 2007, 120:280.e1-7. 10.1016\/j.amjmed.2006.02.015","journal-title":"Am J Med"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1248\/yakushi.20-00010","article-title":"Is concomitant therapy with acetaminophen and low-dose aspirin a risk factor for CKD progression? A 6-year cohort study [Article in Japanese]","volume":"140","author":"Mitsuboshi S","year":"2020","unstructured":"Mitsuboshi S, Yamada H, Yamazaki S, Kobayashi M, Ueno K, Nagai K. Is concomitant therapy with acetaminophen and low-dose aspirin a risk factor for CKD progression? A 6-year cohort study [Article in Japanese]. Yakugaku Zasshi. 2020, 140:943-7. 10.1248\/yakushi.20-00010","journal-title":"Yakugaku Zasshi"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.2215\/CJN.18501120","article-title":"Comparative risks of nonsteroidal anti-inflammatory drugs on CKD","volume":"16","author":"Wan EY","year":"2021","unstructured":"Wan EY, Yu EY, Chan L, et al.. Comparative risks of nonsteroidal anti-inflammatory drugs on CKD. Clin J Am Soc Nephrol. 2021, 16:898-907. 10.2215\/CJN.18501120","journal-title":"Clin J Am Soc Nephrol"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1007\/s40620-016-0352-z","article-title":"Nonsteroidal anti-inflammatory drug use in patients with chronic kidney disease","volume":"30","author":"Heleniak Z","year":"2017","unstructured":"Heleniak Z, Ciepli\u0144ska M, Szychli\u0144ski T, et al.. Nonsteroidal anti-inflammatory drug use in patients with chronic kidney disease. J Nephrol. 2017, 30:781-6. 10.1007\/s40620-016-0352-z","journal-title":"J Nephrol"},{"key":"ref24","article-title":"Nonsteroidal antiinflammatory drugs and risk of gastrointestinal bleeding among patients on hemodialysis","volume":"22","author":"Jankovic SM","year":"2009","unstructured":"Jankovic SM, Aleksic J, Rakovic S, et al.. Nonsteroidal antiinflammatory drugs and risk of gastrointestinal bleeding among patients on hemodialysis. J Nephrol. 2009, 22:502-7.","journal-title":"J Nephrol"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0122899","article-title":"Association of individual non-steroidal anti-inflammatory drugs and chronic kidney disease: A population-based case control study","volume":"10","author":"Ingrasciotta Y","year":"2015","unstructured":"Ingrasciotta Y, Sultana J, Giorgianni F, et al.. Association of individual non-steroidal anti-inflammatory drugs and chronic kidney disease: A population-based case control study. PLoS One. 2015, 10:e0122899. 10.1371\/journal.pone.0122899","journal-title":"PLoS One"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.34067\/KID.0005112020","article-title":"Can NSAIDs be used safely for analgesia in patients with CKD?: CON","volume":"1","author":"Guthrie B","year":"2020","unstructured":"Guthrie B. Can NSAIDs be used safely for analgesia in patients with CKD?: CON. Kidney360. 2020, 1:1189-91. 10.34067\/KID.0005112020","journal-title":"Kidney360"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfn745","article-title":"Acetaminophen, aspirin and progression of advanced chronic kidney disease","volume":"24","author":"Evans M","year":"2009","unstructured":"Evans M, Fored CM, Bellocco R, et al.. Acetaminophen, aspirin and progression of advanced chronic kidney disease. Nephrol Dial Transplant. 2009, 24:1908-18. 10.1093\/ndt\/gfn745","journal-title":"Nephrol Dial Transplant"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1007\/s11255-022-03344-9","article-title":"Non-steroidal anti-inflammatory drugs in chronic kidney disease and risk of acute adverse kidney events according to route of administration","volume":"55","author":"Teo SH","year":"2023","unstructured":"Teo SH, Tan NC, Choo JC, et al.. Non-steroidal anti-inflammatory drugs in chronic kidney disease and risk of acute adverse kidney events according to route of administration. Int Urol Nephrol. 2023, 55:679-86. 10.1007\/s11255-022-03344-9","journal-title":"Int Urol Nephrol"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.34067\/kid.0004582020","article-title":"Can NSAIDs be used safely for analgesia in patients with CKD?: PRO","volume":"1","author":"Barreto EF","year":"2020","unstructured":"Barreto EF, Feely MA. Can NSAIDs be used safely for analgesia in patients with CKD?: PRO. Kidney360. 2020, 1:1184-8. 10.34067\/kid.0004582020","journal-title":"Kidney360"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1053\/j.ajkd.2021.11.007","article-title":"Higher-dose gabapentinoids and the risk of adverse events in older adults with CKD: A population-based cohort study","volume":"80","author":"Muanda FT","year":"2022","unstructured":"Muanda FT, Weir MA, Ahmadi F, et al.. Higher-dose gabapentinoids and the risk of adverse events in older adults with CKD: A population-based cohort study. Am J Kidney Dis. 2022, 80:98-107. 10.1053\/j.ajkd.2021.11.007","journal-title":"Am J Kidney Dis"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjmed.2009.09.030","article-title":"Gabapentin toxicity in patients with chronic kidney disease: A preventable cause of morbidity","volume":"123","author":"Zand L","year":"2010","unstructured":"Zand L, McKian KP, Qian Q. Gabapentin toxicity in patients with chronic kidney disease: A preventable cause of morbidity. Am J Med. 2010, 123:367-73. 10.1016\/j.amjmed.2009.09.030","journal-title":"Am J Med"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2018010096","article-title":"Gabapentin and pregabalin use and association with adverse outcomes among hemodialysis patients","volume":"29","author":"Ishida JH","year":"2018","unstructured":"Ishida JH, McCulloch CE, Steinman MA, Grimes BA, Johansen KL. Gabapentin and pregabalin use and association with adverse outcomes among hemodialysis patients. J Am Soc Nephrol. 2018, 29:1970-8. 10.1681\/ASN.2018010096","journal-title":"J Am Soc Nephrol"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1016\/j.nefro.2020.03.004","article-title":"Prevalence and risk factors of baclofen neurotoxicity in patients with severely impaired renal function","volume":"40","author":"Cheong M","year":"2020","unstructured":"Cheong M, Lee J, Lee TY, Kim SB. Prevalence and risk factors of baclofen neurotoxicity in patients with severely impaired renal function. Nefrologia (Engl Ed). 2020, 40:543-51. 10.1016\/j.nefro.2020.03.004","journal-title":"Nefrologia (Engl Ed)"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.1053\/j.ajkd.2018.11.008","article-title":"Muscle relaxant use among hemodialysis patients: Prevalence, clinical indications, and adverse outcomes","volume":"73","author":"Mina D","year":"2019","unstructured":"Mina D, Johansen KL, McCulloch CE, Steinman MA, Grimes BA, Ishida JH. Muscle relaxant use among hemodialysis patients: Prevalence, clinical indications, and adverse outcomes. Am J Kidney Dis. 2019, 73:525-32. 10.1053\/j.ajkd.2018.11.008","journal-title":"Am J Kidney Dis"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.1016\/j.mayocp.2022.11.004","article-title":"Baclofen and the risk of encephalopathy: A real-world, active-comparator cohort study","volume":"98","author":"Hwang YJ","year":"2023","unstructured":"Hwang YJ, Chang AR, Brotman DJ, Inker LA, Grams ME, Shin JI. Baclofen and the risk of encephalopathy: A real-world, active-comparator cohort study. Mayo Clin Proc. 2023, 98:676-88. 10.1016\/j.mayocp.2022.11.004","journal-title":"Mayo Clin Proc"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.5414\/CP203243","article-title":"Baclofen-induced neurotoxicity in patients with compromised renal function: Review","volume":"56","author":"Salim SA","year":"2018","unstructured":"Salim SA, Thomas L, Achanti A, et al.. Baclofen-induced neurotoxicity in patients with compromised renal function: Review. Int J Clin Pharmacol Ther. 2018, 56:467-75. 10.5414\/CP203243","journal-title":"Int J Clin Pharmacol Ther"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.2147\/JPR.S461032","article-title":"Tizanidine: Advances in pharmacology & therapeutics and drug formulations","volume":"17","author":"Zhu LL","year":"2024","unstructured":"Zhu LL, Wang YH, Zhou Q. Tizanidine: Advances in pharmacology & therapeutics and drug formulations. J Pain Res. 2024, 17:1257-71. 10.2147\/JPR.S461032","journal-title":"J Pain Res"},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.2165\/11319330-000000000-00000","article-title":"Effects of varying degrees of renal impairment on the pharmacokinetics of duloxetine: Analysis of a single-dose phase I study and pooled steady-state data from phase II\/III trials","volume":"49","author":"Lobo ED","year":"2010","unstructured":"Lobo ED, Heathman M, Kuan HY, et al.. Effects of varying degrees of renal impairment on the pharmacokinetics of duloxetine: Analysis of a single-dose phase I study and pooled steady-state data from phase II\/III trials. Clin Pharmacokinet. 2010, 49:311-21. 10.2165\/11319330-000000000-00000","journal-title":"Clin Pharmacokinet"},{"key":"ref39","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbr.2025.115467","article-title":"Depression in chronic kidney disease: Particularities, specific mechanisms and therapeutic considerations, a narrative review","volume":"483","author":"Lefr\u00e8re A","year":"2025","unstructured":"Lefr\u00e8re A, Burtey S, Bobot S, Belzeaux R, Bobot M. Depression in chronic kidney disease: Particularities, specific mechanisms and therapeutic considerations, a narrative review. Behav Brain Res. 2025, 483:115467. 10.1016\/j.bbr.2025.115467","journal-title":"Behav Brain Res"},{"key":"ref40","doi-asserted-by":"publisher","DOI":"10.1038\/s41581-021-00484-6","article-title":"Opioids for chronic pain management in patients with dialysis-dependent kidney failure","volume":"18","author":"Tobin DG","year":"2022","unstructured":"Tobin DG, Lockwood MB, Kimmel PL, et al.. Opioids for chronic pain management in patients with dialysis-dependent kidney failure. Nat Rev Nephrol. 2022, 18:113-28. 10.1038\/s41581-021-00484-6","journal-title":"Nat Rev Nephrol"},{"key":"ref41","doi-asserted-by":"publisher","DOI":"10.2215\/CJN.04770610","article-title":"Opioid and benzodiazepine use in end-stage renal disease: A systematic review","volume":"6","author":"Wyne A","year":"2011","unstructured":"Wyne A, Rai R, Cuerden M, Clark WF, Suri RS. Opioid and benzodiazepine use in end-stage renal disease: A systematic review. Clin J Am Soc Nephrol. 2011, 6:326-33. 10.2215\/CJN.04770610","journal-title":"Clin J Am Soc Nephrol"},{"key":"ref42","doi-asserted-by":"publisher","DOI":"10.1053\/j.ajkd.2019.12.010","article-title":"Association of opioids and nonsteroidal anti-inflammatory drugs with outcomes in CKD: findings from the CRIC (Chronic Renal Insufficiency Cohort) study","volume":"76","author":"Zhan M","year":"2020","unstructured":"Zhan M, Doerfler RM, Xie D, et al.. Association of opioids and nonsteroidal anti-inflammatory drugs with outcomes in CKD: findings from the CRIC (Chronic Renal Insufficiency Cohort) study. Am J Kidney Dis. 2020, 76:184-93. 10.1053\/j.ajkd.2019.12.010","journal-title":"Am J Kidney Dis"},{"key":"ref43","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.45485","article-title":"Opioid prescription in patients with chronic kidney disease: A systematic review of comparing safety and efficacy of opioid use in chronic kidney disease patients","volume":"15","author":"Odoma VA","year":"2023","unstructured":"Odoma VA, Pitliya A, AlEdani E, et al.. Opioid prescription in patients with chronic kidney disease: A systematic review of comparing safety and efficacy of opioid use in chronic kidney disease patients. Cureus. 2023, 15:e45485. 10.7759\/cureus.45485","journal-title":"Cureus"},{"key":"ref44","doi-asserted-by":"publisher","DOI":"10.2215\/CJN.09910917","article-title":"Opioid analgesics and adverse outcomes among hemodialysis patients","volume":"13","author":"Ishida JH","year":"2018","unstructured":"Ishida JH, McCulloch CE, Steinman MA, Grimes BA, Johansen KL. Opioid analgesics and adverse outcomes among hemodialysis patients. Clin J Am Soc Nephrol. 2018, 13:746-53. 10.2215\/CJN.09910917","journal-title":"Clin J Am Soc Nephrol"},{"key":"ref45","doi-asserted-by":"publisher","DOI":"10.1155\/2019\/3865924","article-title":"Opioid safety and concomitant benzodiazepine use in end-stage renal disease patients","volume":"2019","author":"Ruchi R","year":"2019","unstructured":"Ruchi R, Bozorgmehri S, Ozrazgat-Baslanti T, Segal MS, Shukla AM, Mohandas R, Kumar S. Opioid safety and concomitant benzodiazepine use in end-stage renal disease patients. Pain Res Manag. 2019, 2019:3865924. 10.1155\/2019\/3865924","journal-title":"Pain Res Manag"},{"key":"ref46","doi-asserted-by":"publisher","DOI":"10.31662\/jmaj.2023-0020","article-title":"Comparison of intra-articular knee injection of corticosteroid between hemodialysis and non-hemodialysis patients","volume":"6","author":"Tabata Y","year":"2023","unstructured":"Tabata Y, Omori S, Mitsuhashi O, et al.. Comparison of intra-articular knee injection of corticosteroid between hemodialysis and non-hemodialysis patients. JMA J. 2023, 6:307-11. 10.31662\/jmaj.2023-0020","journal-title":"JMA J"},{"key":"ref47","doi-asserted-by":"publisher","DOI":"10.2214\/AJR.23.30458","article-title":"Local and systemic side effects of corticosteroid injections for musculoskeletal indications","volume":"222","author":"Kamel SI","year":"2024","unstructured":"Kamel SI, Rosas HG, Gorbachova T. Local and systemic side effects of corticosteroid injections for musculoskeletal indications. AJR Am J Roentgenol. 2024, 222:e2330458. 10.2214\/AJR.23.30458","journal-title":"AJR Am J Roentgenol"},{"key":"ref48","doi-asserted-by":"publisher","DOI":"10.1016\/j.ekir.2019.08.019","article-title":"Steroid-associated side effects in patients with primary proteinuric kidney disease","volume":"4","author":"Oh GJ","year":"2019","unstructured":"Oh GJ, Waldo A, Paez-Cruz F, et al.. Steroid-associated side effects in patients with primary proteinuric kidney disease. Kidney Int Rep. 2019, 4:1608-16. 10.1016\/j.ekir.2019.08.019","journal-title":"Kidney Int Rep"},{"key":"ref49","article-title":"Polyarticular corticosteroid injection versus systemic administration in treatment of rheumatoid arthritis patients: A randomized controlled study","volume":"32","author":"Furtado RN","year":"2005","unstructured":"Furtado RN, Oliveira LM, Natour J. Polyarticular corticosteroid injection versus systemic administration in treatment of rheumatoid arthritis patients: A randomized controlled study. J Rheumatol. 2005, 32:1691-8.","journal-title":"J Rheumatol"},{"key":"ref50","doi-asserted-by":"publisher","DOI":"10.23876\/j.krcp.18.0143","article-title":"Renal sympathetic nerve activation via \u03b1(2)-adrenergic receptors in chronic kidney disease progression","volume":"38","author":"Jang HS","year":"2019","unstructured":"Jang HS, Kim J, Padanilam BJ. Renal sympathetic nerve activation via \u03b1(2)-adrenergic receptors in chronic kidney disease progression. Kidney Res Clin Pract. 2019, 38:6-14. 10.23876\/j.krcp.18.0143","journal-title":"Kidney Res Clin Pract"},{"key":"ref51","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjms.2024.08.020","article-title":"Epidural block with lidocaine ameliorates kidney function deterioration and fibrosis of chronic kidney disease in rats","volume":"368","author":"Xu X","year":"2024","unstructured":"Xu X, Yu B, Lv Y, et al.. Epidural block with lidocaine ameliorates kidney function deterioration and fibrosis of chronic kidney disease in rats. Am J Med Sci. 2024, 368:660-7. 10.1016\/j.amjms.2024.08.020","journal-title":"Am J Med Sci"},{"key":"ref52","doi-asserted-by":"publisher","DOI":"10.1177\/2054358119828391","article-title":"A review of cannabis in chronic kidney disease symptom management","volume":"6","author":"Ho C","year":"2019","unstructured":"Ho C, Martinusen D, Lo C. A review of cannabis in chronic kidney disease symptom management. Can J Kidney Health Dis. 2019, 6:2054358119828391. 10.1177\/2054358119828391","journal-title":"Can J Kidney Health Dis"},{"key":"ref53","doi-asserted-by":"publisher","DOI":"10.1097\/MNH.0000000000000590","article-title":"The nephrologist's guide to cannabis and cannabinoids","volume":"29","author":"Rein JL","year":"2020","unstructured":"Rein JL. The nephrologist's guide to cannabis and cannabinoids. Curr Opin Nephrol Hypertens. 2020, 29:248-57. 10.1097\/MNH.0000000000000590","journal-title":"Curr Opin Nephrol Hypertens"},{"key":"ref54","doi-asserted-by":"publisher","DOI":"10.17219\/dmp\/193020","article-title":"Efficiency of cannabis and cannabidiol in managing chronic pain syndromes: A comprehensive narrative review","volume":"61","author":"Bort M","year":"2024","unstructured":"Bort M, Olchowy C, Olchowy A, Nawrot-Hadzik I, Smardz J, Wieckiewicz M. Efficiency of cannabis and cannabidiol in managing chronic pain syndromes: A comprehensive narrative review. Dent Med Probl. 2024, 61:765-82. 10.17219\/dmp\/193020","journal-title":"Dent Med Probl"},{"key":"ref55","doi-asserted-by":"publisher","DOI":"10.1007\/s11916-023-01101-w","article-title":"Medical cannabis for chronic nonmalignant pain management","volume":"27","author":"Hameed M","year":"2023","unstructured":"Hameed M, Prasad S, Jain E, et al.. Medical cannabis for chronic nonmalignant pain management. Curr Pain Headache Rep. 2023, 27:57-63. 10.1007\/s11916-023-01101-w","journal-title":"Curr Pain Headache Rep"},{"key":"ref56","article-title":"Efficacy of cannabis-based medicines for pain management: A systematic review and meta-analysis of randomized controlled trials","volume":"20","author":"Aviram J","year":"2017","unstructured":"Aviram J, Samuelly-Leichtag G. Efficacy of cannabis-based medicines for pain management: A systematic review and meta-analysis of randomized controlled trials. Pain Physician. 2017, 20:E755-96.","journal-title":"Pain Physician"},{"key":"ref57","doi-asserted-by":"publisher","DOI":"10.7326\/M17-0155","article-title":"The effects of cannabis among adults with chronic pain and an overview of general harms: A systematic review","volume":"167","author":"Nugent SM","year":"2017","unstructured":"Nugent SM, Morasco BJ, O'Neil ME, et al.. The effects of cannabis among adults with chronic pain and an overview of general harms: A systematic review. Ann Intern Med. 2017, 167:319-31. 10.7326\/M17-0155","journal-title":"Ann Intern Med"},{"key":"ref58","doi-asserted-by":"publisher","DOI":"10.1007\/s11926-017-0693-1","article-title":"Cannabis and cannabinoids for chronic pain","volume":"19","author":"Romero-Sandoval EA","year":"2017","unstructured":"Romero-Sandoval EA, Kolano AL, Alvarado-V\u00e1zquez PA. Cannabis and cannabinoids for chronic pain. Curr Rheumatol Rep. 2017, 19:67. 10.1007\/s11926-017-0693-1","journal-title":"Curr Rheumatol Rep"},{"key":"ref59","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n1034","article-title":"Medical cannabis or cannabinoids for chronic non-cancer and cancer related pain: A systematic review and meta-analysis of randomised clinical trials","volume":"374","author":"Wang L","year":"2021","unstructured":"Wang L, Hong PJ, May C, et al.. Medical cannabis or cannabinoids for chronic non-cancer and cancer related pain: A systematic review and meta-analysis of randomised clinical trials. BMJ. 2021, 374:n1034. 10.1136\/bmj.n1034","journal-title":"BMJ"},{"key":"ref60","doi-asserted-by":"publisher","DOI":"10.1089\/can.2021.0156","article-title":"Clinical practice guidelines for cannabis and cannabinoid-based medicines in the management of chronic pain and co-occurring conditions","volume":"9","author":"Bell AD","year":"2024","unstructured":"Bell AD, MacCallum C, Margolese S, et al.. Clinical practice guidelines for cannabis and cannabinoid-based medicines in the management of chronic pain and co-occurring conditions. Cannabis Cannabinoid Res. 2024, 9:669-87. 10.1089\/can.2021.0156","journal-title":"Cannabis Cannabinoid Res"},{"key":"ref61","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2018.18472","article-title":"Opioids for chronic noncancer pain: A systematic review and meta-analysis","volume":"320","author":"Busse JW","year":"2018","unstructured":"Busse JW, Wang L, Kamaleldin M, et al.. Opioids for chronic noncancer pain: A systematic review and meta-analysis. JAMA. 2018, 320:2448-60. 10.1001\/jama.2018.18472","journal-title":"JAMA"},{"key":"ref62","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n2040","article-title":"Medical cannabis or cannabinoids for chronic pain: A clinical practice guideline","volume":"374","author":"Busse JW","year":"2021","unstructured":"Busse JW, Vankrunkelsven P, Zeng L, et al.. Medical cannabis or cannabinoids for chronic pain: A clinical practice guideline. BMJ. 2021, 374:n2040. 10.1136\/bmj.n2040","journal-title":"BMJ"},{"key":"ref63","doi-asserted-by":"publisher","DOI":"10.1097\/j.pain.0000000000001941","article-title":"Cannabinoids, cannabis, and cannabis-based medicines for pain management: An overview of systematic reviews","volume":"162","author":"Moore RA","year":"2021","unstructured":"Moore RA, Fisher E, Finn DP, et al.. Cannabinoids, cannabis, and cannabis-based medicines for pain management: An overview of systematic reviews. Pain. 2021, 162:S67-79. 10.1097\/j.pain.0000000000001941","journal-title":"Pain"},{"key":"ref64","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD012182.pub2","article-title":"Cannabis-based medicines for chronic neuropathic pain in adults","volume":"3","author":"M\u00fccke M","year":"2018","unstructured":"M\u00fccke M, Phillips T, Radbruch L, Petzke F, H\u00e4user W. Cannabis-based medicines for chronic neuropathic pain in adults. Cochrane Database Syst Rev. 2018, 3:CD012182. 10.1002\/14651858.CD012182.pub2","journal-title":"Cochrane Database Syst Rev"},{"key":"ref65","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2021-054282","article-title":"Long-term and serious harms of medical cannabis and cannabinoids for chronic pain: a systematic review of non-randomised studies","volume":"12","author":"Zeraatkar D","year":"2022","unstructured":"Zeraatkar D, Cooper MA, Agarwal A, et al.. Long-term and serious harms of medical cannabis and cannabinoids for chronic pain: a systematic review of non-randomised studies. BMJ Open. 2022, 12:e054282. 10.1136\/bmjopen-2021-054282","journal-title":"BMJ Open"},{"key":"ref66","doi-asserted-by":"publisher","DOI":"10.1016\/S2468-2667(18)30110-5","article-title":"Effect of cannabis use in people with chronic non-cancer pain prescribed opioids: Findings from a 4-year prospective cohort study","volume":"3","author":"Campbell G","year":"2018","unstructured":"Campbell G, Hall WD, Peacock A, et al.. Effect of cannabis use in people with chronic non-cancer pain prescribed opioids: Findings from a 4-year prospective cohort study. Lancet Public Health. 2018, 3:e341-50. 10.1016\/S2468-2667(18)30110-5","journal-title":"Lancet Public Health"},{"key":"ref67","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(25)00068-7","article-title":"Pharmacotherapy and non-invasive neuromodulation for neuropathic pain: A systematic review and meta-analysis","volume":"24","author":"Soliman N","year":"2025","unstructured":"Soliman N, Moisset X, Ferraro MC, et al.. Pharmacotherapy and non-invasive neuromodulation for neuropathic pain: A systematic review and meta-analysis. Lancet Neurol. 2025, 24:413-28. 10.1016\/S1474-4422(25)00068-7","journal-title":"Lancet Neurol"},{"key":"ref68","doi-asserted-by":"publisher","DOI":"10.1093\/ckj\/sfac275","article-title":"Medical cannabis for pain management in patients undergoing chronic hemodialysis: Randomized, double-blind, cross-over, feasibility study","volume":"16","author":"Kliuk-Ben Bassat O","year":"2023","unstructured":"Kliuk-Ben Bassat O, Schechter M, Ashtamker N, et al.. Medical cannabis for pain management in patients undergoing chronic hemodialysis: Randomized, double-blind, cross-over, feasibility study. Clin Kidney J. 2023, 16:701-10. 10.1093\/ckj\/sfac275","journal-title":"Clin Kidney J"},{"key":"ref69","doi-asserted-by":"publisher","DOI":"10.1089\/can.2021.0044","article-title":"Cannabis use and risk of acute kidney injury in patients with advanced chronic kidney disease transitioning to dialysis","volume":"8","author":"Potukuchi PK","year":"2023","unstructured":"Potukuchi PK, Moradi H, Park F, et al.. Cannabis use and risk of acute kidney injury in patients with advanced chronic kidney disease transitioning to dialysis. Cannabis Cannabinoid Res. 2023, 8:138-47. 10.1089\/can.2021.0044","journal-title":"Cannabis Cannabinoid Res"},{"key":"ref70","doi-asserted-by":"publisher","DOI":"10.1089\/can.2022.0141","article-title":"A retrospective cohort study that examined the impact of cannabis consumption on long-term kidney outcomes","volume":"9","author":"Rein JL","year":"2024","unstructured":"Rein JL, Zeng H, Faulkner GB, et al.. A retrospective cohort study that examined the impact of cannabis consumption on long-term kidney outcomes. Cannabis Cannabinoid Res. 2024, 9:635-45. 10.1089\/can.2022.0141","journal-title":"Cannabis Cannabinoid Res"},{"key":"ref71","doi-asserted-by":"publisher","DOI":"10.1016\/j.xkme.2022.100453","article-title":"Therapeutic cannabis use in kidney disease: A survey of Canadian nephrologists","volume":"4","author":"Gitau K","year":"2022","unstructured":"Gitau K, Howe HS, Ginsberg L, Perl J, Ailon J. Therapeutic cannabis use in kidney disease: A survey of Canadian nephrologists. Kidney Med. 2022, 4:100453. 10.1016\/j.xkme.2022.100453","journal-title":"Kidney Med"},{"key":"ref72","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-014-2517-2","article-title":"The use of low-dose naltrexone (LDN) as a novel anti-inflammatory treatment for chronic pain","volume":"33","author":"Younger J","year":"2014","unstructured":"Younger J, Parkitny L, McLain D. The use of low-dose naltrexone (LDN) as a novel anti-inflammatory treatment for chronic pain. Clin Rheumatol. 2014, 33:451-9. 10.1007\/s10067-014-2517-2","journal-title":"Clin Rheumatol"},{"key":"ref73","doi-asserted-by":"publisher","DOI":"10.1002\/phar.2086","article-title":"The safety and efficacy of low\u2010dose naltrexone in the management of chronic pain and inflammation in multiple sclerosis, fibromyalgia, Crohn\u2019s disease, and other chronic pain disorders","volume":"38","author":"Patten DK","year":"2018","unstructured":"Patten DK, Schultz BG, Berlau DJ. The safety and efficacy of low\u2010dose naltrexone in the management of chronic pain and inflammation in multiple sclerosis, fibromyalgia, Crohn\u2019s disease, and other chronic pain disorders. Pharmacotherapy. 2018, 38:382-9. 10.1002\/phar.2086","journal-title":"Pharmacotherapy"},{"key":"ref74","doi-asserted-by":"publisher","DOI":"10.2147\/JPR.S389957","article-title":"Low-dose naltrexone (LDN) for chronic pain at a single institution: A case series","volume":"16","author":"McKenzie-Brown AM","year":"2023","unstructured":"McKenzie-Brown AM, Boorman DW, Ibanez KR, Agwu E, Singh V. Low-dose naltrexone (LDN) for chronic pain at a single institution: A case series. J Pain Res. 2023, 16:1993-8. 10.2147\/JPR.S389957","journal-title":"J Pain Res"},{"key":"ref75","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.81086","article-title":"Therapeutic uses and efficacy of low-dose naltrexone: A scoping review","volume":"17","author":"Leiber KK","year":"2025","unstructured":"Leiber KK, Parker RW. Therapeutic uses and efficacy of low-dose naltrexone: A scoping review. Cureus. 2025, 17:e81086. 10.7759\/cureus.81086","journal-title":"Cureus"},{"key":"ref76","doi-asserted-by":"publisher","DOI":"10.1080\/15360288.2024.2302550","article-title":"Efficacy and safety of low dose naltrexone for chronic pain","volume":"38","author":"N Irwin M","year":"2024","unstructured":"N Irwin M, A Cooke D, Berland D, D Marshall V, A Smith M. Efficacy and safety of low dose naltrexone for chronic pain. J Pain Palliat Care Pharmacother. 2024, 38:13-9. 10.1080\/15360288.2024.2302550","journal-title":"J Pain Palliat Care Pharmacother"},{"key":"ref77","doi-asserted-by":"publisher","DOI":"10.2147\/JPR.S451183","article-title":"Effective doses of low-dose naltrexone for chronic pain - an observational study","volume":"17","author":"Marcus NJ","year":"2024","unstructured":"Marcus NJ, Robbins L, Araki A, Gracely EJ, Theoharides TC. Effective doses of low-dose naltrexone for chronic pain - an observational study. J Pain Res. 2024, 17:1273-84. 10.2147\/JPR.S451183","journal-title":"J Pain Res"},{"key":"ref78","doi-asserted-by":"publisher","DOI":"10.3390\/jcm12093256","article-title":"Narrative review: Low-dose ketamine for pain management","volume":"12","author":"Riccardi A","year":"2023","unstructured":"Riccardi A, Guarino M, Serra S, et al.. Narrative review: Low-dose ketamine for pain management. J Clin Med. 2023, 12:3256. 10.3390\/jcm12093256","journal-title":"J Clin Med"},{"key":"ref79","doi-asserted-by":"publisher","DOI":"10.1016\/j.kint.2021.03.041","article-title":"The prevalence of pain among patients with chronic kidney disease using systematic review and meta-analysis","volume":"100","author":"Lambourg E","year":"2021","unstructured":"Lambourg E, Colvin L, Guthrie G, et al.. The prevalence of pain among patients with chronic kidney disease using systematic review and meta-analysis. Kidney Int. 2021, 100:636-49. 10.1016\/j.kint.2021.03.041","journal-title":"Kidney Int"},{"key":"ref80","doi-asserted-by":"publisher","DOI":"10.1016\/j.kint.2017.04.019","article-title":"Challenges in conducting clinical trials in nephrology: conclusions from a Kidney Disease-Improving Global Outcomes (KDIGO) Controversies Conference","volume":"92","author":"Baigent C","year":"2017","unstructured":"Baigent C, Herrington WG, Coresh J, et al.. Challenges in conducting clinical trials in nephrology: conclusions from a Kidney Disease-Improving Global Outcomes (KDIGO) Controversies Conference. Kidney Int. 2017, 92:297-305. 10.1016\/j.kint.2017.04.019","journal-title":"Kidney Int"},{"key":"ref81","doi-asserted-by":"publisher","DOI":"10.1002\/pds.1962","article-title":"Analgesic use and the risk for progression of chronic kidney disease","volume":"19","author":"Kuo HW","year":"2010","unstructured":"Kuo HW, Tsai SS, Tiao MM, Liu YC, Lee IM, Yang CY. Analgesic use and the risk for progression of chronic kidney disease. Pharmacoepidemiol Drug Saf. 2010, 19:745-51. 10.1002\/pds.1962","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"ref82","doi-asserted-by":"publisher","DOI":"10.1111\/hdi.12622","article-title":"Management of pain in end-stage renal disease patients: Short review","volume":"22","author":"Raina R","year":"2018","unstructured":"Raina R, Krishnappa V, Gupta M. Management of pain in end-stage renal disease patients: Short review. Hemodial Int. 2018, 22:290-6. 10.1111\/hdi.12622","journal-title":"Hemodial Int"},{"key":"ref83","doi-asserted-by":"publisher","DOI":"10.1093\/ckj\/sfab242","article-title":"Chronic prescription of antidepressant medication in patients with chronic kidney disease with and without kidney replacement therapy compared with matched controls in the Dutch general population","volume":"15","author":"van Oosten MJ","year":"2022","unstructured":"van Oosten MJ, Koning D, Logtenberg SJ, et al.. Chronic prescription of antidepressant medication in patients with chronic kidney disease with and without kidney replacement therapy compared with matched controls in the Dutch general population. Clin Kidney J. 2022, 15:778-85. 10.1093\/ckj\/sfab242","journal-title":"Clin Kidney J"},{"key":"ref84","doi-asserted-by":"publisher","DOI":"10.1093\/ckj\/sfab121","article-title":"Local anesthetics for the Nephrologist","volume":"15","author":"Uppal NN","year":"2022","unstructured":"Uppal NN, Jhaveri M, Hong S, Shore-Lesserson L, Jhaveri KD, Izzedine H. Local anesthetics for the Nephrologist. Clin Kidney J. 2022, 15:186-93. 10.1093\/ckj\/sfab121","journal-title":"Clin Kidney J"},{"key":"ref85","doi-asserted-by":"publisher","DOI":"10.1016\/j.transproceed.2012.12.014","article-title":"Anesthesia and kidney transplantation","volume":"45","author":"Ricaurte L","year":"2013","unstructured":"Ricaurte L, Vargas J, Lozano E, D\u00edaz L. Anesthesia and kidney transplantation. Transplant Proc. 2013, 45:1386-91. 10.1016\/j.transproceed.2012.12.014","journal-title":"Transplant Proc"},{"key":"ref86","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.74272","article-title":"Effect of regional anesthesia on intraoperative hyperkalemia in patients with chronic kidney disease: Two case reports","volume":"16","author":"Oura S","year":"2024","unstructured":"Oura S, Okada M, Miyashita R. Effect of regional anesthesia on intraoperative hyperkalemia in patients with chronic kidney disease: Two case reports. Cureus. 2024, 16:e74272. 10.7759\/cureus.74272","journal-title":"Cureus"},{"key":"ref87","doi-asserted-by":"publisher","DOI":"10.1159\/000365821","article-title":"What every doctor should know about drug safety in patients with chronic kidney disease","author":"Paparella M","year":"2015","unstructured":"Paparella M, Martina V, Rizzo MA, Gallieni M. What every doctor should know about drug safety in patients with chronic kidney disease. Contributions to Nephrology. Widmer MK, Malik J (ed): S. Karger AG, Basel; 2015. 184:24-50. 10.1159\/000365821"},{"key":"ref88","doi-asserted-by":"publisher","DOI":"10.36106\/gjra\/1211160","article-title":"USG guided femoral & lateral cutaneous nerve block as saviour-anaesthetic management of patient of CKD-ESRD with difficult airway & coagulopathy posted for novel prosthetic femoro-femoral av fistula","volume":"10","author":"Kumar V","year":"2021","unstructured":"Kumar V, Vashist V, Gupta B. USG guided femoral & lateral cutaneous nerve block as saviour-anaesthetic management of patient of CKD-ESRD with difficult airway & coagulopathy posted for novel prosthetic femoro-femoral av fistula. Glob J Res Anal. 2021, 10:122-3. 10.36106\/gjra\/1211160","journal-title":"Glob J Res Anal"},{"key":"ref89","doi-asserted-by":"publisher","DOI":"10.1177\/10892532251334691","article-title":"Regional nerve blocks used in renal transplantation and donor nephrectomy: A narrative review","volume":"29","author":"Hill-Oliva M","year":"2025","unstructured":"Hill-Oliva M, Smith NK, Wang R. Regional nerve blocks used in renal transplantation and donor nephrectomy: A narrative review. Semin Cardiothorac Vasc Anesth. 2025, 29:265-78. 10.1177\/10892532251334691","journal-title":"Semin Cardiothorac Vasc Anesth"},{"key":"ref90","doi-asserted-by":"publisher","DOI":"10.4103\/1658-354X.125955","article-title":"Clonidine for management of chronic pain: A brief review of the current evidences","volume":"8","author":"Kumar A","year":"2014","unstructured":"Kumar A, Maitra S, Khanna P, Baidya DK. Clonidine for management of chronic pain: A brief review of the current evidences. Saudi J Anaesth. 2014, 8:92-6. 10.4103\/1658-354X.125955","journal-title":"Saudi J Anaesth"},{"key":"ref91","doi-asserted-by":"publisher","DOI":"10.1159\/000525424","article-title":"The safety and efficacy of clonidine in hemodialysis patients: A systematic review and meta-analysis","volume":"107","author":"Derk G","year":"2022","unstructured":"Derk G, Barton A, An R, Fang HY, Ashrafi SA, Wilund K. The safety and efficacy of clonidine in hemodialysis patients: A systematic review and meta-analysis. Pharmacology. 2022, 107:545-55. 10.1159\/000525424","journal-title":"Pharmacology"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/447423-the-present-and-future-of-pain-management-in-patients-with-chronic-kidney-disease-a-narrative-review","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,31]],"date-time":"2025-12-31T14:58:39Z","timestamp":1767193119000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/447423-the-present-and-future-of-pain-management-in-patients-with-chronic-kidney-disease-a-narrative-review"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,31]]},"references-count":91,"URL":"https:\/\/doi.org\/10.7759\/cureus.100490","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12,31]]}}}